Details
| Original language | English |
|---|---|
| Article number | 2100713 |
| Journal | Small Methods |
| Volume | 5 |
| Issue number | 11 |
| Early online date | 23 Sept 2021 |
| Publication status | Published - 12 Nov 2021 |
Abstract
The past year has established the link between the COVID-19 pandemic and the global spread of severe fungal infections; thus, underscoring the critical need for rapid and realizable fungal disease diagnostics. While in recent years, health authorities, such as the Centers for Disease Control and Prevention, have reported the alarming emergence and spread of drug-resistant pathogenic fungi and warned against the devastating consequences, progress in the diagnosis and treatment of fungal infections is limited. Early diagnosis and patient-tailored therapy are established to be key in reducing morbidity and mortality associated with fungal (and cofungal) infections. As such, antifungal susceptibility testing (AFST) is crucial in revealing susceptibility or resistance of these pathogens and initiating correct antifungal therapy. Today, gold standard AFST methods require several days for completion, and thus this much delayed time for answer limits their clinical application. This review focuses on the advancements made in developing novel AFST techniques and discusses their implications in the context of the practiced clinical workflow. The aim of this work is to highlight the advantages and drawbacks of currently available methods and identify the main gaps hindering their progress toward clinical application.
Keywords
- diagnostics, drug resistance, fungal pathogens, microfluidics, rapid antifungal susceptibility testing
ASJC Scopus subject areas
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Small Methods, Vol. 5, No. 11, 2100713, 12.11.2021.
Research output: Contribution to journal › Review article › Research › peer review
}
TY - JOUR
T1 - Paving the Way to Overcome Antifungal Drug Resistance
T2 - Current Practices and Novel Developments for Rapid and Reliable Antifungal Susceptibility Testing
AU - Heuer, Christopher
AU - Bahnemann, Janina
AU - Scheper, Thomas
AU - Segal, Ester
N1 - Funding Information: The authors acknowledge the financial support from the German Research Foundation (DFG) via the grant SCHE 279/32‐1 and the Lower Saxony Ministry for Science and Culture, Research Cooperation Lower Saxony–Israel. E.S. is grateful for the support of the Israeli Innovation Authority (via Kamin Project 65025) and J.B. acknowledges the support of the Emmy Noether Programme (346772917).
PY - 2021/11/12
Y1 - 2021/11/12
N2 - The past year has established the link between the COVID-19 pandemic and the global spread of severe fungal infections; thus, underscoring the critical need for rapid and realizable fungal disease diagnostics. While in recent years, health authorities, such as the Centers for Disease Control and Prevention, have reported the alarming emergence and spread of drug-resistant pathogenic fungi and warned against the devastating consequences, progress in the diagnosis and treatment of fungal infections is limited. Early diagnosis and patient-tailored therapy are established to be key in reducing morbidity and mortality associated with fungal (and cofungal) infections. As such, antifungal susceptibility testing (AFST) is crucial in revealing susceptibility or resistance of these pathogens and initiating correct antifungal therapy. Today, gold standard AFST methods require several days for completion, and thus this much delayed time for answer limits their clinical application. This review focuses on the advancements made in developing novel AFST techniques and discusses their implications in the context of the practiced clinical workflow. The aim of this work is to highlight the advantages and drawbacks of currently available methods and identify the main gaps hindering their progress toward clinical application.
AB - The past year has established the link between the COVID-19 pandemic and the global spread of severe fungal infections; thus, underscoring the critical need for rapid and realizable fungal disease diagnostics. While in recent years, health authorities, such as the Centers for Disease Control and Prevention, have reported the alarming emergence and spread of drug-resistant pathogenic fungi and warned against the devastating consequences, progress in the diagnosis and treatment of fungal infections is limited. Early diagnosis and patient-tailored therapy are established to be key in reducing morbidity and mortality associated with fungal (and cofungal) infections. As such, antifungal susceptibility testing (AFST) is crucial in revealing susceptibility or resistance of these pathogens and initiating correct antifungal therapy. Today, gold standard AFST methods require several days for completion, and thus this much delayed time for answer limits their clinical application. This review focuses on the advancements made in developing novel AFST techniques and discusses their implications in the context of the practiced clinical workflow. The aim of this work is to highlight the advantages and drawbacks of currently available methods and identify the main gaps hindering their progress toward clinical application.
KW - diagnostics
KW - drug resistance
KW - fungal pathogens
KW - microfluidics
KW - rapid antifungal susceptibility testing
UR - http://www.scopus.com/inward/record.url?scp=85115359985&partnerID=8YFLogxK
U2 - 10.1002/smtd.202100713
DO - 10.1002/smtd.202100713
M3 - Review article
AN - SCOPUS:85115359985
VL - 5
JO - Small Methods
JF - Small Methods
IS - 11
M1 - 2100713
ER -